27 May, 2017
The stock's market cap is $793.28 million. It conducts its activities through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum. Therefore 100% are positive. TherapeuticsMD TXMD had 2 analyst reports since March 23, 2017 according to SRatingsIntel. TherapeuticsMD now has a consensus rating of "Buy" and an average price target of $20.57. On Tuesday, December 8 the stock rating was maintained by Jefferies with "Buy".
Banco Santander, S.A. (ADR) (NYSE:SAN) have shown a low EPS growth of -5.00% in the last 5 years and has earnings growth of 13.20% yoy. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Earnest Prtn Ltd Llc holds 115 shares. 1492 Capital Mngmt Lc invested in 269,858 shares. Over the last three months, the shares of the company have changed 22.00% and performed 49.64% over the last six months. TherapeuticsMD comprises approximately 0.8% of Sphera Funds Management LTD.'s investment portfolio, making the stock its 25th largest position. Kistler, a Alabama-based fund reported 1,000 shares. Analysts have a mean recommendation of 4.00 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).
Whereas they predicted High and Low Earnings Estimate as $-0.08 and $-0.15 respectively. Jefferies Group LLC restated a "buy" rating and issued a $18.00 price objective on shares of TherapeuticsMD in a research report on Thursday, March 2nd. UNH was included in 5 notes of analysts from October 19, 2016. The rating was maintained by Stifel Nicolaus on Tuesday, December 8 with "Buy".
04/09/2017 - TherapeuticsMD, Inc. had its "outperform" rating reiterated by analysts at Cowen. The rating was initiated by Piper Jaffray with "Overweight" on Wednesday, January 4. The stock had a trading volume of 1,886,122 shares.
Investors and Traders continue to monitor technical levels of shares of Nokia Corporation (NOK). TherapeuticsMD Inc (TXMD) has declined 46.30% since May 24, 2016 and is downtrending. It has underperformed by 63.00% the S&P500.
Investors sentiment increased to 1.54 in 2016 Q4. The company has Beta Value of 1.23 and ATR value of 0.32. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company's stock valued at $207,000 after buying an additional 10,330 shares during the period. 31 funds opened positions while 46 raised stakes. Conte Mark had sold 5,195 shares worth $51,798. Geode Capital Ltd Liability Com owns 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 1.16M shares. Schwab Charles Inv Mgmt accumulated 566,083 shares.
More notable recent TherapeuticsMD Inc (NYSEMKT:TXMD) news were published by: Prnewswire.com which released: "RM LAW Announces Class Action Lawsuit Against TherapeuticsMD, Inc." on April 26, 2017, also Globenewswire.com with their article: "IMPORTANT THERAPEUTICSMD, INC". Moreover, Jpmorgan Chase Company has 0.02% invested in TherapeuticsMD Inc (NYSEMKT:TXMD). Fmr Limited Liability Co reported 29.49M shares or 0.02% of all its holdings. 209.08 million shares or 1.98% more from 205.02 million shares in 2016Q3 were reported. Commerzbank Aktiengesellschaft Fi reported 54,128 shares or 0% of all its holdings. The last session's volume of 9.38 million shares was lower than its average volume of 10.05 million shares. Amalgamated Natl Bank stated it has 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). State Board Of Administration Of Florida Retirement invested in 73,923 shares.
05/08/2015 - TherapeuticsMD, Inc. was downgraded to "sell" by analysts at Zacks. Century Inc holds 136,277 shares or 0% of its portfolio.
- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
